GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HUTCHMED (China) Ltd (NAS:HCM) » Definitions » Research & Development

HUTCHMED (China) (HUTCHMED (China)) Research & Development : $302.0 Mil (TTM As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is HUTCHMED (China) Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. HUTCHMED (China)'s Research & Development for the six months ended in Dec. 2023 was $157.4 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was $302.0 Mil.

HUTCHMED (China) Research & Development Historical Data

The historical data trend for HUTCHMED (China)'s Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HUTCHMED (China) Research & Development Chart

HUTCHMED (China) Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 91.94 174.78 299.09 386.89 302.00

HUTCHMED (China) Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 176.04 181.74 205.15 144.63 157.37

HUTCHMED (China) Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $302.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HUTCHMED (China)  (NAS:HCM) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

HUTCHMED (China) Research & Development Related Terms

Thank you for viewing the detailed overview of HUTCHMED (China)'s Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

HUTCHMED (China) (HUTCHMED (China)) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HUTCHMED (China) Ltd (NAS:HCM) » Definitions » Research & Development
Comparable Companies
LSE:INDV LSE:BMK LSE:HIK LSE:APH LSE:AGY LSE:ANCR LSE:EAH LSE:VLG LSE:CEL LSE:STX ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA TSE:4507 VTRS NBIX XSWX:SDZ
Traded in Other Exchanges
00013:Hong Kong HCM.GB:UK HCM:UK H7T2:Germany
Address
2 Queen's Road Central, 48th Floor, Cheung Kong Center, Hong Kong, HKG
Website
https://www.hutch-med.com
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.